Plus   Neg

Nektar Therapeutics Posts Wider Loss In Q4 - Quick Facts

Nektar Therapeutics (NKTR) reported a fourth-quarter net loss per share of $0.64 compared to a loss of $0.57, a year ago. On average, 13 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.68, for the quarter. Analysts' estimates typically exclude special items.

Fourth-quarter revenue was $33.9 million compared to $39.8 million, a year ago. Analysts expected revenue of $26.93 million for the quarter.

Cash and investments in marketable securities at December 31, 2019 were approximately $1.6 billion as compared to $1.9 billion at December 31, 2018.

Shares of Nektar Therapeutics were up 5% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT